The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 1, 2013, Pages 174-182

  Solesio, María E ^a   Prime, Tracy A ^b   Logan, Angela ^b   Murphy, Michael P ^b   del Mar Arroyo Jimenez, María ^c   Jordán, Joaquín ^c   Galindo, María F ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Bax; Drp1; Fission; Mitochondrial dynamics; ROS

Indexed keywords

[10 (4,5 DIMETHOXY 2 METHYL 3,6 DIOXO 1,4 CYCLOHEXADIEN 1 YL)DECYL]TRIPHENYLPHOSPHONIUM; ALKYL GROUP; ANTIOXIDANT; CARBON; CARBONYL DERIVATIVE; CATION; DYNAMIN I; METHYLTRIPHENYLPHOSPHONIUM; MITOFUSIN 1; MITOFUSIN 2; OXIDOPAMINE; PROTEIN BAX; UBIQUINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL CULTURE; CELL STRUCTURE; CONTROLLED STUDY; COVALENT BOND; CYTOSOL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DRUG TARGETING; GENE TRANSLOCATION; IN VITRO STUDY; LIPID PEROXIDATION; LIPOPHILICITY; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; MITOCHONDRION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT DURATION;

ANTIOXIDANTS; CELL LINE; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DYNAMICS; ORGANOPHOSPHORUS COMPOUNDS; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; UBIQUINONE;

EID: 84868574626     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.07.009     Document Type: Article

References (47)

1. Obeso J.A., Rodriguez-Oroz M.C., Goetz C.G., Marin C., Kordower J.H., Rodriguez M., Hirsch E.C., Farrer M., Schapira A.H., Halliday G. Missing pieces in the Parkinson's disease puzzle. Nat. Med. 2010, 16:653-661.
2. Jordan J., Groot P.W., Galindo M.F. Mitochondria: the headquarters in ischemia-induced neuronal death. Cent. Nerv. Syst. Agents Med. Chem. 2011, 11:98-106.
3. Galindo M.F., Ikuta I., Zhu X., Casadesus G., Jordan J. Mitochondrial biology in Alzheimer's disease pathogenesis. J. Neurochem. 2010, 114:933-945.
4. Martin L.J. Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2006, 65:1103-1110.
5. Jordan J., Cena V., Prehn J.H. Mitochondrial control of neuron death and its role in neurodegenerative disorders. J. Physiol. Biochem. 2003, 59:129-141.
6. Finkel T. Radical medicine: treating ageing to cure disease. Nat. Rev. Mol. Cell Biol. 2005, 6:971-976.
7. Abou-Sleiman P.M., Muqit M.M., Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 2006, 7:207-219.
8. Greenamyre J.T., Hastings T.G. Biomedicine. Parkinson's-divergent causes, convergent mechanisms. Science 2004, 304:1120-1122.
9. Skulachev V.P. How to clean the dirtiest place in the cell: cationic antioxidants as intramitochondrial ROS scavengers. IUBMB Life 2005, 57:305-310.
10. Murphy M.P. Targeting lipophilic cations to mitochondria. Biochim. Biophys. Acta 2008, 1777:1028-1031.
11. Subramanian S., Kalyanaraman B., Migrino R.Q. Mitochondrially targeted antioxidants for the treatment of cardiovascular diseases. Recent Pat. Cardiovasc. Drug Discov. 2010, 5:54-65.
12. Kelso G.F., Porteous C.M., Coulter C.V., Hughes G., Porteous W.K., Ledgerwood E.C., Smith R.A.J., Murphy M.P. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J. Biol. Chem. 2001, 276:4588-4596.
13. James A.M., Cochemé H.M., Smith R.A.J., Murphy M.P. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J. Biol. Chem. 2005, 280:21295-21312.
14. Sanjuan-Pla A., Cervera A.M., Apostolova N., Garcia-Bou R., Victor V.M., Murphy M.P., McCreath K.J. A targeted antioxidant reveals the importance of mitochondrial reactive oxygen species in the hypoxic signaling of HIF-1alpha. FEBS Lett. 2005, 579:2669-2674.
15. James A.M., Sharpley M.S., Manas A.R., Frerman F.E., Hirst J., Smith R.A.J., Murphy M.P. Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. J. Biol. Chem. 2007, 282:14708-14718.
16. Cochemé H.M., Kelso G.F., James A.M., Ross M.F., Trnka J., Mahendiran T., Asin-Cayuela J., Blaikie F.H., Manas A.R., Porteous C.M., Adlam V.J., Smith R.A.J., Murphy M.P. Mitochondrial targeting of quinones: therapeutic implications. Mitochondrion 2007, 7(Suppl.):S94-S102.
17. Gane E.J., Weilert F., Orr D.W., Keogh G.F., Gibson M., Lockhart M.M., Frampton C.M., Taylor K.M., Smith R.A.J., Murphy M.P. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 2010, 30:1019-1026.
18. Snow B.J., Rolfe F.L., Lockhart M.M., Frampton C.M., O'Sullivan J.D., Fung V., Smith R.A.J., Murphy M.P., Taylor K.M. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov. Disord. 2010, 25:1670-1674.
19. Duty S., Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol. 2011, 164:1357-1391.
20. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 2001, 65:135-172.
21. Gomez-Lazaro M., Galindo M.F., Concannon C.G., Segura M.F., Fernandez-Gomez F.J., Llecha N., Comella J.X., Prehn J.H., Jordan J. 6-Hydroxydopamine activates the mitochondrial apoptosis pathway through p38 MAPK-mediated, p53-independent activation of Bax and PUMA. J. Neurochem. 2008, 104:1599-1612.
22. Gomez-Lazaro M., Bonekamp N.A., Galindo M.F., Jordan J., Schrader M. 6-Hydroxydopamine (6-OHDA) induces Drp1-dependent mitochondrial fragmentation in SH-SY5Y cells. Free Radic. Biol. Med. 2008, 44:1960-1969.
23. Chen H., Chan D.C. Mitochondrial dynamics - fusion, fission, movement, and mitophagy - in neurodegenerative diseases. Hum. Mol. Genet. 2009, 18:R169-R176.
24. Reddy P.H., Reddy T.P., Manczak M., Calkins M.J., Shirendeb U., Mao P. Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Res. Rev. 2011, 67:103-118.
25. Manczak M., Mao P., Calkins M.J., Cornea A., Reddy A.P., Murphy M.P., Szeto H.H., Park B., Reddy P.H. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J. Alzheimers Dis. 2010, 20(Suppl. 2):S609-S631.
26. Barsoum M.J., Yuan H., Gerencser A.A., Liot G., Kushnareva Y., Graber S., Kovacs I., Lee W.D., Waggoner J., Cui J., White A.D., Bossy B., Martinou J.C., Youle R.J., Lipton S.A., Ellisman M.H., Perkins G.A., Bossy-Wetzel E. Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J. 2006, 25:3900-3911.
27. Solesio M.E., Saez-Atienzar S., Jordan J., Galindo M.F. 3-Nitropropionioc acid induces autophagy by mitochondrial permeability transition pore formation rather than activation of the mitochondrial fission pathway. Br. J. Pharmacol. Apr 18 2012, http://dx.doi.org/10.1111/j.1476-5381.2012.01994.x (Epub ahead of print) (PMID: 22509855).
28. Jordan J., Galindo M.F., Tornero D., Gonzalez-Garcia C., Cena V. Bcl-x L blocks mitochondrial multiple conductance channel activation and inhibits 6-OHDA-induced death in SH-SY5Y cells. J. Neurochem. 2004, 89:124-133.
29. Prime T.A., Forkink M., Logan A., Finichiu P.G., McLachlan J., Li Pun P.B., Koopman W.J., Larsen L., Latter M.J., Smith R.A.J., Murphy M.P. A ratiometric fluorescent probe for assessing mitochondrial phospholipid peroxidation within living cells. Free Radic. Biol. Med. 2012, 53:544-553.
30. Lee Y.J., Jeong S.Y., Karbowski M., Smith C.L., Youle R.J. Roles of the mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and Opa1 in apoptosis. Mol. Biol. Cell 2004, 15:5001-5011.
31. Gee P., Davison A.J. Intermediates in the aerobic autoxidation of 6-hydroxydopamine: relative importance under different reaction conditions. Free Radic. Biol. Med. 1989, 6:271-284.
32. Jordan J., Galindo M.F., Tornero D., Gonzalez-Garcia C., Cena V. Bcl-x L blocks mitochondrial multiple conductance channel activation and inhibits 6-OHDA-induced death in SH-SY5Y cells. J. Neurochem. 2004, 89:124-133.
33. Fernandez-Gomez F.J., Pastor M.D., Garcia-Martinez E.M., Melero-Fernandez de Mera R., Gou-Fabregas M., Gomez-Lazaro M., Calvo S., Soler R.M., Galindo M.F., Jordan J. Pyruvate protects cerebellar granular cells from 6-hydroxydopamine-induced cytotoxicity by activating the Akt signaling pathway and increasing glutathione peroxidase expression. Neurobiol. Dis. 2006, 24:296-307.
34. Galindo M.F., Jordan J., Gonzalez-Garcia C., Cena V. Chromaffin cell death induced by 6-hydroxydopamine is independent of mitochondrial swelling and caspase activation. J. Neurochem. 2003, 84:1066-1073.
35. Smith R.A.J., Murphy M.P. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann. N. Y. Acad. Sci. 2010, 1201:96-103.
36. Chacko B.K., Reily C., Srivastava A., Johnson M.S., Ye Y., Ulasova E., Agarwal A., Zinn K.R., Murphy M.P., Kalyanaraman B., Darley-Usmar V. Prevention of diabetic nephropathy in Ins2(+/)(AkitaJ) mice by the mitochondria-targeted therapy MitoQ. Biochem. J. 2010, 432:9-19.
37. Adlam V.J., Harrison J.C., Porteous C.M., James A.M., Smith R.A.J., Murphy M.P., Sammut I.A. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J. 2005, 19:1088-1095.
38. Chandran K., Aggarwal D., Migrino R.Q., Joseph J., McAllister D., Konorev E.A., Antholine W.E., Zielonka J., Srinivasan S., Avadhani N.G., Kalyanaraman B. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys. J. 2009, 96:1388-1398.
39. Legesse-Miller A., Massol R.H., Kirchhausen T. Constriction and Dnm1p recruitment are distinct processes in mitochondrial fission. Mol. Biol. Cell 2003, 14:1953-1963.
40. Ingerman E., Perkins E.M., Marino M., Mears J.A., McCaffery J.M., Hinshaw J.E., Nunnari J. Dnm1 forms spirals that are structurally tailored to fit mitochondria. J. Cell Biol. 2005, 170:1021-1027.
41. Karbowski M., Jeong S.Y., Youle R.J. Endophilin B1 is required for the maintenance of mitochondrial morphology. J. Cell Biol. 2004, 166:1027-1039.
42. Mozdy A.D., McCaffery J.M., Shaw J.M. Dnm1p GTPase-mediated mitochondrial fission is a multi-step process requiring the novel integral membrane component Fis1p. J. Cell Biol. 2000, 151:367-380.
43. Otsuga D., Keegan B.R., Brisch E., Thatcher J.W., Hermann G.J., Bleazard W., Shaw J.M. The dynamin-related GTPase, Dnm1p, controls mitochondrial morphology in yeast. J. Cell Biol. 1998, 143:333-349.
44. Cerveny K.L., McCaffery J.M., Jensen R.E. Division of mitochondria requires a novel DMN1-interacting protein, Net2p. Mol. Biol. Cell 2001, 12:309-321.
45. Labrousse A.M., Zappaterra M.D., Rube D.A., van der Bliek A.M. C. elegans dynamin-related protein DRP-1 controls severing of the mitochondrial outer membrane. Mol. Cell 1999, 4:815-826.
46. Perez-Alvarez S., Solesio M.E., Manzanares J., Jordan J., Galindo M.F. Lactacystin requires reactive oxygen species and Bax redistribution to induce mitochondria-mediated cell death. Br. J. Pharmacol. 2009, 158:1121-1130.
47. Karbowski M., Lee Y.J., Gaume B., Jeong S.Y., Frank S., Nechushtan A., Santel A., Fuller M., Smith C.L., Youle R.J. Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. J. Cell Biol. 2002, 159:931-938.